glp 1 merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh Merck moves into obesity with

The American Academy of Pediatrics and major obstetric societies suggest delaying GLP-1 initiation or considering alternatives during active breastfeeding

In fact, it represents one of modern medicine's oldest and most persistent challenges

Key questions to discuss include: Whether you meet NHS criteria for GLP-1 prescription (type 2 diabetes or obesity with complications) The evidenceor lack thereoffor GLP-1 use specifically in Hashimoto's management Potential interactions between GLP-1 medications and thyroid hormone replacement How GLP-1 therapy might affect your thyroid function monitoring schedule Alternative evidence-based approaches to managing metabolic symptoms in Hashimoto's The costs and practicalities of private prescription if NHS funding is not available Contraception requirements if you are of childbearing potential (GLP-1 medications should be avoided in pregnancy and breastfeeding) Your GP may recommend optimising your current thyroid management first , ensuring your levothyroxine dose is appropriate and that you are not over- or under-replaced

Other studies have also noted thyroid hormone changes in people with obesity who were treated with semaglutide